Top Trends Driving Innovation and Change in the Anti-Asthmatics And COPD Drugs Market: Innovative FDC Drug Indacaterol Plus Mometasone Strengthens Leading Companies In The Anti-Asthmatics And COPD Drugs Market
Discover trends, market shifts, and competitive outlooks for the anti-asthmatics and copd drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Projected Market Size and Growth Rates for the Anti-Asthmatics And COPD Drugs Market From 2025 To 2029?
The market size of anti-asthmatics and COPD drugs has shown robust growth in the last years. From 2024’s $80.82 billion, it will jump to $86.11 billion in 2025, with a compound annual growth rate (CAGR) of 6.6%. The historical growth is attributable to factors such as growing respiratory disease rates, higher instances of tobacco smoking, global warming, an aging population, emerging markets, new techniques in drug discovery, and an increase in healthcare spending.
Expectations suggest a robust growth trajectory for the anti-asthmatics and COPD drugs market in the forthcoming years, with its value predicted to reach $107.01 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 5.6%. This forthcoming growth within the predicted timespan could be linked to various factors. These include the rising popularity of e-cigarettes/vaping, escalating obesity rates, advancements in technology, a significant undiagnosed population, and the use of anti-asthmatics and COPD drugs in treating COVID-19 patients, along with a heightened intake of fatty foods. Key trends for the forecast period comprise the development of probiotic drugs for asthma and anti-il-5 drugs to diversify business portfolios. Additionally, the introduction of innovative products is expected to strengthen and maintain market presence amidst stiff competition, increased investment in bioelectric medicine development, a rise in collaborations, personalized treatment provision, and the development of combination drugs for enhanced effectiveness. The development of biologics is also underway to cater to the burgeoning demand.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp
What External and Internal Drivers Are Contributing to the Growth of theAnti-Asthmatics And COPD Drugs Market?
Adjustable risk elements, like smoking, absence of exercise, and unhealthy diet, are major contributors to the growth of the market for anti-asthmatics and COPD medicines. Despite a global reduction in smoking, rising smoking rates are seen in developing nations like China, India, Indonesia, and Nigeria. For instance, the population of tobacco users in Indonesia is expected to rise by 24 million and by 7 million in Nigeria by 2025. Over 40% of the world’s total cigarette consumption is in China. High-income countries, including the USA and Europe, have a higher intake of fats, including saturated fatty acids a risk factor for Asthma and COPD. According to the World Health Organization, in developed economies, fats account for more than 35% of the total energy requirements, compared to less than 20% in low-income countries and under 25% in lower-middle-income countries.
What Segment Types Define the Anti-Asthmatics And COPD Drugs Market Structure?
The anti-asthmatics and COPD drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=3802&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Anti-Asthmatics And COPD Drugs Market?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Long-Term Trends Are Transforming the Competitive Landscape of the Anti-Asthmatics And COPD Drugs Market?
Leading businesses in the anti-asthmatics and COPD drugs sector are developing novel products such as fixed-dose combination (FDC) medication, Indacaterol plus Mometasone in order to enhance their market profitability. Utilized through the Breezhaler device, Indacaterol plus Mometasone is a single daily FDC drug engineered for the continuous treatment of asthma patients. For instance, Glenmark Pharmaceuticals, a US-based firm, unveiled an innovative fixed-dose combination (FDC) drug, Indacaterol plus Mometasone, in June 2022. This was specifically for patients in India facing intractable asthma. Marketed under the name Indamet, it is available in three different forms, each embedding a steady dose of Indacaterol of 150 mcg, whereas Mometasone has varied dosages: 80 mcg, 160 mcg, and 320 mcg.
View the full report here:
What Is the Definition of the Anti-Asthmatics And COPD Drugs Market?
Anti-asthmatic and chronic obstructive pulmonary disease drugs refer to drugs that are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3802
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
